ScinoPharm Taiwan, Ltd.
1789.TW
Price:
$17.3
Market Cap:
$13.68B
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2011-09-29
Stock Exchange
TAI
Ticker
1789.TW
PE Ratio
[72.08]
ROE
[1.95%]
Current Ratio
[5.34]
Dividend Yield
[2.02%]
Enterprise Value
[11.32B]
Dividend History
The PE Ratio as of December 2025 (TTM) for ScinoPharm Taiwan, Ltd. (1789.TW) is 72.08
According to ScinoPharm Taiwan, Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 72.08. This represents a change of -32.32% compared to the average of 106.50 of the last 4 quarters.
ScinoPharm Taiwan, Ltd. (1789.TW) Historical PE Ratio (quarterly & annually)
How has 1789.TW PE Ratio performed in the past?
The mean historical PE Ratio of ScinoPharm Taiwan, Ltd. over the last ten years is 65.61. The current 72.08 PE Ratio has changed 10.89% with respect to the historical average. Over the past ten years (40 quarters), 1789.TW's PE Ratio was at its highest in in the December 2020 quarter at 722.19. The PE Ratio was at its lowest in in the December 2023 quarter at 32.78.
Average
65.61
Median
64.70
Minimum
43.11
Maximum
97.08
ScinoPharm Taiwan, Ltd. (1789.TW) PE Ratio by Quarter and Year
Discovering the peaks and valleys of ScinoPharm Taiwan, Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 125.20%
Maximum Annual PE Ratio = 97.08
Minimum Annual Increase = -36.09%
Minimum Annual PE Ratio = 43.11
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | 51.38 | -29.13% |
| 2023 | 72.50 | 27.25% |
| 2022 | 56.97 | -28.83% |
| 2021 | 80.06 | -1.01% |
| 2020 | 80.88 | -16.69% |
| 2019 | 97.08 | 125.20% |
| 2018 | 43.11 | -36.09% |
| 2017 | 67.45 | 50.66% |
| 2016 | 44.77 | -27.72% |
| 2015 | 61.94 | -24.07% |
ScinoPharm Taiwan, Ltd. (1789.TW) Average PE Ratio
How has 1789.TW PE Ratio performed in the past?
The current PE Ratio of ScinoPharm Taiwan, Ltd. (1789.TW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
60.28
5-year avg
68.36
10-year avg
65.61
ScinoPharm Taiwan, Ltd. (1789.TW) PE Ratio vs. Peers
How is 1789.TW’s PE Ratio compared to its peers?
ScinoPharm Taiwan, Ltd.’s PE Ratio is greater than YungShin Global Holding Corporation (15.18), greater than Foresee Pharmaceuticals Co., Ltd. (-8.64), greater than Ever Supreme Bio Technology Co., Ltd (36.48), greater than Synmosa Biopharma Corporation (24.19), greater than Standard Chem & Pharm Co. Ltd. (14.22), greater than Visco Vision Inc. (15.56), greater than Excelsior Medical Co., Ltd. (17.66), greater than United Orthopedic Corporation (23.35), greater than Tanvex BioPharma, Inc. (-9.60), greater than Grape King Bio Ltd (14.38),
| Company | PE Ratio | Market cap |
|---|---|---|
| 15.18 | $15.02B | |
| -8.64 | $12.55B | |
| 36.48 | $14.80B | |
| 24.19 | $16.30B | |
| 14.22 | $11.44B | |
| 15.56 | $10.93B | |
| 17.66 | $14.00B | |
| 23.35 | $11.57B | |
| -9.60 | $14.96B | |
| 14.38 | $19.26B |
Build a custom stock screener for ScinoPharm Taiwan, Ltd. (1789.TW) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ScinoPharm Taiwan, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ScinoPharm Taiwan, Ltd. (1789.TW) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ScinoPharm Taiwan, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is ScinoPharm Taiwan, Ltd.'s PE Ratio?
How is the PE Ratio calculated for ScinoPharm Taiwan, Ltd. (1789.TW)?
What is the highest PE Ratio for ScinoPharm Taiwan, Ltd. (1789.TW)?
What is the 3-year average PE Ratio for ScinoPharm Taiwan, Ltd. (1789.TW)?
What is the 5-year average PE Ratio for ScinoPharm Taiwan, Ltd. (1789.TW)?
How does the current PE Ratio for ScinoPharm Taiwan, Ltd. (1789.TW) compare to its historical average?